
Epigral Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Epigral targets consistent growth aligned with its expansion and diversification strategy (Page 17).
- Volume growth is expected around 20-29% year-on-year, driven mainly by derivatives and specialty chemicals (Page 11).
- FY25 revenue is estimated in the Rs. 2,500 to 2,600 crore range, with PAT around Rs. 300 to 350 crore (Page 11).
- Capacity utilization for new capacities is expected around 80-85% in coming years (Page 9).
- New CAPEX will focus on derivatives and specialty chemicals, targeting ~70% revenue contribution by FY27/FY28 (Pages 9, 12).
- Derivative product volumes and values are projected to grow, aided by new product development and capacity ramp-up (Page 13).
- Conservative EBITDA margin guidance is around 25% for the full year, with potential upside if derivatives prices improve (Pages 14-15).
See what Epigral management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Current CAPEX planned for this year is around Rs. 300 crore, primarily funded through internal accruals.
- Future CAPEX plans will be evaluated for funding through a mix of internal accruals, debt, and possibly equity raising.
- No firm decision yet on raising funds via preferential allotment or fresh equity issuance, but these options remain open depending on CAPEX requirements.
- Management confirmed focus on reducing debt from current Rs. 960 crore to around Rs. 850-900 crore by year-end after CAPEX spend.
- Any new fundraising, whether debt or equity, will be considered at the appropriate time aligned with CAPEX announcements and board approvals expected in the next 3 months.
See what Epigral management said on order book — free account, 30 seconds.
Capex plans
Yes- Current year CAPEX planned: Approximately Rs. 300 crore, including maintenance CAPEX (~1-1.5% of gross block) and new investments.
- Key ongoing projects:
- - CPVC compound plant commissioned on June 29, 2024; ramp-up expected by end of Q3 and optimized contribution by Q4 FY25.
- - Chlorotoluene plant commissioning delayed; expected completion by end of Q2 FY25 with staggered block-wise commissioning through September.
- Future CAPEX focus:
- - Priority on downstream chlorine derivatives and specialty chemicals with a target ROCE of around 25%.
- - Several projects under evaluation, with announcements and approvals expected within 3 months.
- Funding: Current CAPEX funded via internal accruals; future CAPEX may involve a mix of internal accruals, debt, or market raising.
- Strategic aim: Increase revenue share from derivatives and specialty chemicals to 70% by FY28, emphasizing import substitution and multi-product diversification.
Track Epigral — get its next earnings analysis in your feed
How does Epigral rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Epigral rank in Chemicals & Petrochemicals?
Compare Epigral against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…